FDA Approved: RYDAPT — Supplemental Application (Novartis Pharmaceuticals Corporation)

View source ↗

Summary

The FDA approved a supplemental application for RYDAPT (midostaurin) submitted by Novartis Pharmaceuticals Corporation. The approval updates the drug’s labeling…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia with Flt3 Mutation
• Systemic Mastocytosis

Drugs mentioned

• Rydapt (midostaurin)

Snippet

SUPPL AP for RYDAPT (RYDAPT)